Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trimebutine 3-thiocarbamoylbenzenesulfonate

Drug Profile

Trimebutine 3-thiocarbamoylbenzenesulfonate

Alternative Names: GIC-1001; TB-905-02

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antibe Therapeutics
  • Developer gIcare Pharma
  • Class Antispasmodics; Benzenesulfonates; Benzoic acids; Irritable bowel syndrome therapies; Opioid analgesics; Organic sulfur compounds; Phenylbutyrates
  • Mechanism of Action Muscarinic receptor antagonists; Neurotransmitter modulators; Opioid kappa receptor agonists; Opioid mu receptor agonists; Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Irritable bowel syndrome; Procedural pain

Most Recent Events

  • 17 Feb 2016 No recent reports on development identified - Phase-II for Procedural pain in USA and Canada (PO)
  • 17 Feb 2016 No recent reports on development identified - Preclinical for Irritable bowel syndrome in Canada (PO)
  • 01 Dec 2014 gIcare Pharma completes a phase Ib trial in healthy volunteers in Canada (NCT02276768)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top